Related Experiment Video
Updated: Jan 31, 2026

Bioluminescence-Based Tumor Quantification Method for Monitoring Tumor Progression and Treatment Effects in Mouse Lymphoma Models
Published on: July 7, 2016
Progressive diffuse large B-cell lymphoma with TP53 gene mutation treated with chidamide-based chemotherapy
Qing Li1, Jingcao Huang1, Yang Ou1
1Department of Hematology & Hematology Research Laboratory, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China.
Abstract:
We attempted to explore novel treatment options for progressive diffuse large B-cell lymphoma (DLBCL) with TP53 mutation that has a poor response to rituximab-based immunochemotherapy. Herein, we report the case of a patient with DLBCL having TP53 mutation who showed progression following four cycles of rituximab-based immunochemotherapy but achieved sustained partial remission following chidamide-based chemotherapy. In vitro experiments performed using the DLBCL cell lines OCI-ly1 (LY1; mutant TP53), OCI-ly10 (LY10; wild-type TP53) and OCI-ly19 (LY19, wild-type TP53) demonstrated that chidamide is more potent against cells with mutant TP53 mutant than those with wild-type TP53. Moreover, chidamide can reduce the mRNA and protein expression levels of mutant TP53 and upregulate the surface expression of the CD20 antigen in lymphoma cells.
Related Concept Videos
Mutation, Gene Flow, and Genetic Drift
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Diffusion
Diffusion
Viral Mutations

